I-Mab (IMAB) Stock Price, News & Analysis

Company Overview

I-Mab is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel biologics to treat cancer and autoimmune disorders. Founded in 2016 and headquartered in Shanghai, China with U.S. operations in Rockville, Maryland, the company applies its proprietary immunology platforms to identify and advance first-in-class and best-in-class antibody therapies. I-Mab’s research capabilities span antibody engineering, translational biology and process development, supporting a broad pipeline of drug candidates targeting the immune system.

The company’s pipeline includes multiple monoclonal antibody therapies in various stages of clinical development. Key programs address immune-oncology indications, with agents designed to modulate immune checkpoints and enhance anti-tumor responses. In parallel, I-Mab is advancing antibodies for autoimmune diseases, aiming to restore immune balance in conditions such as rheumatoid arthritis and systemic lupus erythematosus. Its development strategy encompasses single-agent and combination regimens, reflecting the company’s commitment to creating differentiated therapies.

I-Mab serves global markets through strategic collaborations and partnerships with multinational biopharmaceutical firms. The company leverages its dual presence in China and the United States to facilitate cross-border clinical trials and regulatory engagements. By combining insights from both regions, I-Mab aims to accelerate patient access to its therapeutic candidates and address unmet medical needs in diverse patient populations.

The leadership team at I-Mab brings together experienced executives in biotechnology R&D, clinical development and regulatory affairs. Guided by a board of directors with deep industry expertise, the company has established a robust governance framework to support its growth. As it advances its pipeline through late-stage studies, I-Mab remains focused on delivering innovative biologics that harness the power of the immune system for patients worldwide.

Key Stats

• Today's Range: $4.49 to $4.77
• 50-Day Range: $3.42 to $6.56
• 52-Week Range: $0.81 to $6.79
• Volume: 1.51 million shs
• Average Volume: 1.61 million shs
• Market Capitalization: $388.29 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

I-Mab Stock Analysis - MarketRank™

I-Mab scored higher than 1% of companies evaluated by MarketBeat, and ranked 905th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

I-Mab has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

I-Mab has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for I-Mab are expected to decrease in the coming year, from ($0.56) to ($1.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of I-Mab is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of I-Mab is -13.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

I-Mab has a P/B Ratio of 1.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IMAB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

I-Mab does not currently pay a dividend.

Dividend Growth

I-Mab does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for IMAB on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, I-Mab insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.10% of the stock of I-Mab is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

38.38% of the stock of I-Mab is held by institutions.

Company Calendar

• Last Earnings: 8/20/2025
• Today: 10/28/2026
• ESMO 2026: 11/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IMAB
• CIK: 1778016
• Web: www.i-mabbiopharma.com
• Phone: 86-21-6057-8000
• Fax: N/A
• Employees: 380
• Year Founded: 2016

Profitability

• EPS (Trailing Twelve Months): ($0.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$22.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -19.65%
• Return on Assets: -18.58%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.82
• Quick Ratio: 22.82

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.47 per share
• Price / Book: 1.93

Miscellaneous

• Outstanding Shares: 81,660,000
• Free Float: 63,613,000
• Market Cap: $388.29 million
• Optionable: Optionable
• Beta: 1.45